Resveratrol dose-dependently upregulates GDF15 mRNA, protein expression, and secretion in both murine embryonic fibroblasts and human HepG2 liver cells. Transcriptome analysis identified ATF3 as the transcriptional mediator linking resveratrol's activation of p38 MAPK signaling to GDF15 induction. In vivo, resveratrol-treated mice resisted high-fat diet-induced obesity, showed elevated circulating GDF15, increased GDF15 expression across liver, kidney, and colon tissues, and demonstrated enhanced downstream ERK signaling in the brain — suggesting a gut-liver-brain axis mechanism.
GDF15 has emerged as a compelling metabolic hormone: it suppresses appetite via GFRAL receptors in the hindbrain and is elevated during cellular stress, exercise, and caloric restriction. Identifying resveratrol as a pharmacological GDF15 inducer adds mechanistic clarity to years of inconsistent obesity data for this polyphenol. The p38-ATF3 axis is a known stress-response pathway, raising the question of whether resveratrol's benefits are partly a hormetic stress signal rather than a direct metabolic reprogramming effect.
Critical limitations temper enthusiasm: this remains a preclinical mouse study with cell-line validation. Human resveratrol bioavailability is notoriously poor, and translating hepatic GDF15 induction to meaningful anti-obesity outcomes in humans is unproven. Still, the mechanistic specificity here — a named transcription factor, quantified tissue distribution, and confirmed CNS signaling — elevates this above typical polyphenol work. Confirmatory human trials measuring circulating GDF15 after resveratrol dosing are now a logical next step.
